Literature DB >> 17498686

Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat.

Melinda L Cox1, Victoria L Haller, Sandra P Welch.   

Abstract

We have shown in past isobolographic studies that a small amount of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) can enhance morphine antinociception in mice. However, previous studies of the Delta(9)-THC/morphine interaction were performed using normal mice or rats and evaluated acute thermal antinociception. Less is known about cannabinoid and opioid interactions involved in mechanical nociception and in chronic inflammatory pain models, such as Freund's complete adjuvant-induced arthritic model. One fixed-ratio combination was chosen for testing the interaction between Delta(9)-THC and morphine in the Freund's adjuvant-induced arthritic model. This combination represented a 1:1 ratio of the drugs and thus consisted of equieffective doses ranging from 0.1 to 5 mg/kg Delta(9)-THC and from 0.1 to 5 mg/kg morphine. The combination ED(50) value for the fixed ratios (total dose) in relation to the ED(50) value of the drugs alone was determined. The isobolographic analysis indicated a synergistic interaction between Delta(9)-THC and morphine in both the non-arthritic and the arthritic rats. Since Freund's adjuvant-induced alteration in endogenous opioid tone has been previously shown, our data indicate that such changes did not preclude the use of Delta(9)-THC and morphine in combination. As with acute preclinical pain models in which the Delta(9)-THC/morphine combination results in less tolerance development, the implication of the study for chronic pain conditions is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498686     DOI: 10.1016/j.ejphar.2007.04.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

1.  Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.

Authors:  David R Maguire; Charles P France
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

2.  Opioid and cannabinoid synergy in a mouse neuropathic pain model.

Authors:  Nicholas P Kazantzis; Sherelle L Casey; Patrick W Seow; Vanessa A Mitchell; Christopher W Vaughan
Journal:  Br J Pharmacol       Date:  2016-07-13       Impact factor: 8.739

Review 3.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

4.  The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.

Authors:  Jenny L Wilkerson; Sudeshna Ghosh; Mohammed Mustafa; Rehab A Abdullah; Micah J Niphakis; Roberto Cabrera; Rafael L Maldonado; Benjamin F Cravatt; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2016-11-25       Impact factor: 5.250

5.  Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.

Authors:  Ziva D Cooper; Gillinder Bedi; Divya Ramesh; Rebecca Balter; Sandra D Comer; Margaret Haney
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

6.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

7.  The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids.

Authors:  Adrianne R Wilson-Poe; Edvinas Pocius; Melissa Herschbach; Michael M Morgan
Journal:  Pharmacol Biochem Behav       Date:  2012-10-10       Impact factor: 3.533

Review 8.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

Review 9.  The analgesic potential of cannabinoids.

Authors:  Jaseena Elikkottil; Jaseena Elikottil; Pankaj Gupta; Kalpna Gupta
Journal:  J Opioid Manag       Date:  2009 Nov-Dec

10.  Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.

Authors:  David R Maguire; Charles P France
Journal:  Eur J Pharmacol       Date:  2016-05-13       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.